EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Revisiting the Lipid–Cancer Axis: PCSK9, ANGPTL3, and CETP as Emerging Biomarkers and Therapeutic Targets in Oncology

Dimitris C Kounatidis iD, Natalia G Vallianou iD, Fotis Panagopoulos, Antonios Bampiolakis, Vasileios Stamatopoulos, Maria Dalamaga iD, Iordanis Mourouzis, Constantinos Pantos

Biomolecules · 04.06.2026 · 16 (6) · 831

DOI: 10.3390/biom16060831 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 04.06.2026. Verfasst von Dimitris C Kounatidis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Center, First Department of Propaedeutic Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of …. Hauptthemen laut MEDLINE: Neoplasms, Biomarkers, Tumor, Proprotein Convertase 9, Cholesterol Ester Transfer Proteins. Die Arbeit nennt 191 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer remains a major global health challenge, with persistent limitations in early diagnosis, metastatic disease control, and the achievement of durable therapeutic responses with acceptable toxicity. These challenges highlight the need for more precise biomarkers and more effective therapeutic strategies. Increasing evidence implicates dysregulated lipid metabolism as a central contributor to tumor development and progression. In recent years, proprotein convertase subtilisin/kexin type 9 (PCSK9), angiopoietin-like protein 3 (ANGPTL3), and cholesteryl ester transfer protein (CETP) have gained particular attention due to their roles in cholesterol homeostasis, oncogenic signaling, and immune modulation within the tumor microenvironment (TME). This narrative review evaluates the potential of these lipid-regulatory mediators as diagnostic biomarkers and therapeutic targets in oncology. The majority of available evidence derives from preclinical and epidemiological studies, with PCSK9 representing the most extensively investigated target. Findings are sometimes contradictory and strongly influenced by tumor type, disease stage, and biological context, which currently precludes the clinical applicability of these molecules as reliable biomarkers. Similar limitations apply to their translational potential as actionable therapeutic targets. Nevertheless, emerging preclinical evidence suggests that modulation of these glycoproteins may enhance the efficacy of chemotherapy, targeted therapies, and immunotherapy, including nanomedicine-based approaches. Of note, clinical research investigating the role of PCSK9 inhibition in oncology is currently ongoing, whereas comparable studies focusing on ANGPTL3 and CETP remain scarce. Overall, further mechanistic, translational, and prospective clinical investigations are warranted to elucidate the involvement of these lipid-regulatory proteins in cancer biology and to define their potential integration into future oncologic diagnostic and therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsBiomarkers, TumorProprotein Convertase 9Cholesterol Ester Transfer ProteinsAngiopoietin-like ProteinsLipid MetabolismHumansAngiopoietin-Like Protein 3AnimalsTumor MicroenvironmentMolecular Targeted Therapy

Stichwörter der Autor:innen

ANGPTL3CETPPCSK9cancerchemotherapydiagnosisimmune checkpoint inhibitorslipid metabolismtumor microenvironment

Substanzen

Biomarkers, TumorProprotein Convertase 9Cholesterol Ester Transfer ProteinsAngiopoietin-Like Protein 3Angiopoietin-like ProteinsANGPTL3 protein, humanCETP protein, humanPCSK9 protein, human

Autor:innen und Institutionen

  • Diabetes Center, First Department of Propaedeutic Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • Department of Pharmacology, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • First Department of Internal Medicine, Sismanogleio General Hospital, 15126 Athens, Greece.
  • Emergency Department, Evangelismos General Hospital, 10676 Athens, Greece.
  • Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.

ORCID-Profile: Dimitris C Kounatidis, Natalia G Vallianou, Maria Dalamaga

Zitieren

APA

Kounatidis, D. C., Vallianou, N. G., Panagopoulos, F., Bampiolakis, A., Stamatopoulos, V., Dalamaga, M., Mourouzis, I., & Pantos, C. (2026). Revisiting the Lipid–Cancer Axis: PCSK9, ANGPTL3, and CETP as Emerging Biomarkers and Therapeutic Targets in Oncology. Biomolecules, 16(6), 831. https://doi.org/10.3390/biom16060831

Vancouver

Kounatidis DC, Vallianou NG, Panagopoulos F, Bampiolakis A, Stamatopoulos V, Dalamaga M, et al. Revisiting the Lipid–Cancer Axis: PCSK9, ANGPTL3, and CETP as Emerging Biomarkers and Therapeutic Targets in Oncology. Biomolecules. 2026;16(6):831. doi:10.3390/biom16060831

BibTeX
@article{Kounatidis2026,
  author = {Kounatidis, Dimitris C and Vallianou, Natalia G and Panagopoulos, Fotis and Bampiolakis, Antonios and Stamatopoulos, Vasileios and Dalamaga, Maria and Mourouzis, Iordanis and Pantos, Constantinos},
  title = {Revisiting the Lipid–Cancer Axis: PCSK9, ANGPTL3, and CETP as Emerging Biomarkers and Therapeutic Targets in Oncology},
  journal = {Biomolecules},
  year = {2026},
  volume = {16},
  number = {6},
  pages = {831},
  doi = {10.3390/biom16060831}
}
Kostenlos starten →